Sun Pharmaceutical Industries Limited shareholders approved the reclassification of certain individuals from the Promoter Group to the Public shareholder category on September 26, 2026. This decision aligns with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The approval follows a series of intimations issued by the company on May 14, May 22, May 26, August 6, and August 25, 2026. The move formalizes the change in status for the persons referred to in the initial May 14 intimation.

Impact on Shareholding Patterns

The company stated that the effect of this reclassification will be reflected in subsequent quarterly shareholding patterns. These filings will be submitted to stock exchanges in accordance with applicable SEBI Listing Regulations provisions.

Procedural Compliance

The intimation was made in compliance with SEBI Listing Regulations requirements regarding changes in promoter group composition. The Company Secretary and Compliance Officer, Anoop Deshpande, signed the digital submission confirming the shareholder approval.

Sun Pharmaceutical Industries Limited reported a net profit of ₹11,479 crore for FY26, marking a 5% increase year-on-year. The pharmaceutical major logged gross sales of ₹58,220 crore, reflecting a 12% growth compared to the previous fiscal year.

The company’s operational performance remained robust, with EBITDA rising 16% YoY to ₹17,731 crore. This expansion was supported by improved profitability metrics, as the EBITDA margin widened to 30.3% in FY26 from 29.0% in FY25. Gross margins also saw a steady upward trajectory, reaching 80.2% in FY26.

Segment-wise Revenue Performance

The revenue mix highlights the company's diversified global footprint, with international markets contributing significantly to the top line. India formulations remain the largest segment by contribution, followed closely by US formulations.

Emerging Markets demonstrated strong momentum with sales growing 19% YoY to ₹11,187 crore. The Rest of World segment also posted healthy growth, with revenues expanding 19% YoY to ₹8,568 crore. In contrast, US Formulations grew at a moderate pace of 3.6% YoY, reaching ₹16,824 crore.

What the Numbers Show

A divergence is visible between the robust double-digit revenue growth and the single-digit net profit expansion. While top-line figures expanded 12%, net profit grew only 5%. This gap is largely attributable to exceptional items disclosed in the financial notes. The adjusted net profit, which excludes these non-recurring provisions, stood at ₹12,402 crore, showing a more modest 3% increase. The reported profit includes adjustments for items such as GxMDL provisions and wage code impacts, which weighed on the bottom line despite strong operational cash flows.

Balance Sheet and Cash Flow Strength

Sun Pharma maintained a strong balance sheet position, characterized by significant cash reserves and low leverage. Net cash (excluding debt) increased to ₹30,140 crore in FY26 from ₹26,790 crore in FY25. The company’s cash and bank balances stood at ₹11,603 crore as of March 31, 2026.

Operating cash flow remained healthy, with net cash from operating activities at ₹12,420 crore for FY26. Free cash flow was recorded at ₹8,810 crore, indicating ample liquidity for future investments and shareholder returns.

R&D and Manufacturing Footprint

The company continues to prioritize innovation, with R&D spending accounting for 6.1% of sales in FY26. Cumulative R&D spend has reached approximately ₹34,500 crore to date. The innovative medicines portfolio now contributes 22% of total sales, up from 7.3% in FY18, signaling a strategic shift toward higher-value products.

Manufacturing capabilities span 40 facilities globally, supporting operations in over 100 countries. The company employs over 47,000 people worldwide and maintains a leadership position in the Indian pharmaceutical market with an 8.5% market share.